Review decision date: April 2014
This guideline should not be updated at this time. For further information, please refer to the Surveillance Review Decision.
Please note that the 8-year surveillance review did not include consideration of the section of the guideline on progestogen-only subdermal implant. This section of the guideline at the time of the surveillance review was in the process of being updated by the guideline updates standing committee. This addendum update was subsequently published on 03 September 2014.
Next review date: TBC
The NICE guideline on long-acting reversible contraception (LARC) offers best-practice advice for all women of reproductive age who may wish to regulate their fertility using LARC methods. It covers specific issues for the use of these methods during the menarche and before the menopause, and by particular groups, including women who have HIV, learning disabilities or physical disabilities, or are younger than 16 years.
The guideline was previously called long-acting reversible contraception (update).
The addendum to NICE guideline CG30 updates the recommendations on progestogen-only subdermal implants in section 1.5 of the guideline. The addendum also contains details of the methods and evidence used to update these recommendations. The progestogen-only subdermal implant Implanon, previously recommended in this guideline, is no longer available and has been replaced by Nexplanon. Nexplanon contains the same amount of the same drug as Implanon, but the summaries of product characteristics for the two devices are not identical.